Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 12/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | FNTB | P49356 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.31 |
| ▸ | ITGAV | P06756 | 1/20 | 0.31 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.31 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6018280 | 0.93 | CXCR4 (0.37) | CXCR4ADORA2AFNTAFNTBHDAC1 | |
| SCHEMBL6018467 | 0.90 | CXCR4 (0.36) | CXCR4ADORA2AFNTAFNTBHDAC1 | |
| SCHEMBL6018114 | 0.89 | CXCR4 (0.36) | CXCR4ADORA2AFNTAFNTBHDAC1 | |
| SCHEMBL6018194 | 0.88 | FNTA (0.38) | CXCR4ADORA2AFNTAFNTBHDAC1 | |
| SCHEMBL6018478 | 0.87 | CXCR4 (0.36) | CXCR4ADORA2AFNTAFNTBHDAC1 | |
| SCHEMBL6018210 | 0.81 | CXCR4 (0.39) | CXCR4ADORA2AFNTAFNTBHDAC1 | |
| SCHEMBL6018964 | 0.80 | CXCR4 (0.38) | CXCR4ADORA2AHDAC1HDAC6CNR2 | |
| SCHEMBL6018202 | 0.78 | CXCR4 (0.47) | CXCR4ADORA2AFNTAFNTBHDAC1 | |
| SCHEMBL7024499 | 0.78 | HDAC1 (0.42) | CXCR4HDAC1HDAC6ITGAVITGB6 | |
| SCHEMBL6018347 | 0.78 | FOLH1 (0.37) | CXCR4ADORA2AFNTAFNTBHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157818-A1 | Cxcr4-antagonistic drugs composed of nitrogen-containing compound | KUREHA CORPORATION (JP) | 2004-08-12 | — | — | US | disclosed |
| EP-1389460-A1 | CXCR4-ANTAGONISTIC DRUGS COMPRISING NITROGEN-CONTAINING COMPOUND | Kureha Chemical Industry Co., Ltd. (JP) | 2004-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157818-A1 | Cxcr4-antagonistic drugs composed of nitrogen-containing compound | CXCR4, CXCR1, CXCR2 | CXCR4 1/4885ADORA2A 82/4885FNTA 3116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.